MARKET

PRTA

PRTA

Prothena
NASDAQ
22.24
-1.04
-4.47%
After Hours: 22.24 0 0.00% 16:01 04/12 EDT
OPEN
23.14
PREV CLOSE
23.28
HIGH
23.33
LOW
21.92
VOLUME
526.23K
TURNOVER
0
52 WEEK HIGH
79.65
52 WEEK LOW
21.90
MARKET CAP
1.19B
P/E (TTM)
-8.0495
1D
5D
1M
3M
1Y
5Y
J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?
NASDAQ · 20h ago
Cantor Fitzgerald Reiterates Overweight on Prothena Corp
Benzinga · 2d ago
Weekly Report: what happened at PRTA last week (0401-0405)?
Weekly Report · 4d ago
Weekly Report: what happened at PRTA last week (0325-0329)?
Weekly Report · 04/01 09:16
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
NASDAQ · 03/26 15:21
Weekly Report: what happened at PRTA last week (0318-0322)?
Weekly Report · 03/25 09:16
Labcorp expands Alzheimer's testing portfolio with new diagnostic
Healthcare Labcorp expands Alzheimer's testing portfolio with new diagnostic. The pTau217 test is designed to identify phosphorylated tau 217, a key blood-based biomarker in the disease. Alzheimer's is the most common form of dementia and an estimated 6.7M Americans suffer from the condition.
Seeking Alpha · 03/20 13:00
Weekly Report: what happened at PRTA last week (0311-0315)?
Weekly Report · 03/18 09:16
More
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Webull offers Prothena Corporation PLC stock information, including NASDAQ: PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.